The expression and role of serum response factor in papillary carcinoma of the thyroid

HEE JIN KIM1, KYUNG RYOUL KIM1,2,4, HO SUNG PARK1,2,4, KYU YUN JANG1,2, MYOUNG JA CHUNG1,2, MINHO SHONG5 and WOO SUNG MOON1,2,3,4

1Department of Pathology, Chonbuk National University, Medical School, 2Institute for Medical Sciences, 3Diabetes Research Center, 4The Center for Healthcare Technology Development, Jeonju, Chonbuk 561-756; 5Department of Internal Medicine, Chungnam National University, Medical School, Daejeon, Chungnam 301-747, Korea

Received February 16, 2009; Accepted April 28, 2009

Abstract. Serum response factor (SRF) is a transcription factor of the MADS box family. SRF is involved in various cellular processes such as expression of immediate early and tissue-specific genes, cell proliferation, differentiation and apoptosis. The expression of SRF in papillary thyroid carcinoma (PTC) and its role have not been investigated, forming the basis for this study. Surgical specimens of 63 conventional PTCs along with 30 follicular adenoma, 30 adenomatous hyperplasia and 9 anaplastic carcinoma specimens were obtained from the surgical archives. The expression of SRF was determined by the use of immunohistochemical staining. We also investigated the expression level of SRF and an SRF target gene, c-fos in fresh PTC tissues and thyroid cancer cell lines (NPA, FRO and ARO) by Western blot analyses. In addition, we examined the role of SRF in PTC by overexpression of SRF in the NPA cell line. SRF was mainly expressed in cancer cells, showing a strong nuclear and/or cytoplasmic staining in PTC. SRF was expressed in 50 of 63 cases of papillary carcinoma (79%), 18 of 30 cases of follicular adenoma (60%), 10 of 30 cases of nodular hyperplasia (33%) and 6 of 9 cases of anaplastic carcinoma (67%). The expression level of SRF was significantly up-regulated in PTC (combined staining score of 5.21±0.43) and anaplastic carcinoma (5.67±1.45) compared to that of follicular adenoma (2.30±0.44) (P<0.001), or adenomatous goiter (1.13±0.28) (P<0.001). Western blot analyses showed an increased expression of the spliced form of SRF protein and c-Fos protein in PTC as compared to non-tumor thyroid tissues. SRF expression correlated with the tumor size of the PTCs (P<0.05). Overexpression of SRF in papillary carcinoma cells enhanced cell motility and invasiveness. Our results indicate that the altered expression of SRF in papillary carcinoma cells may play an important role in PTC carcinogenesis and progression.

Introduction

Serum response factor (SRF) is a transcription factor of the MADS box family (1,2). To date, DNA binding sites for SRFs (serum response elements-SREs) have been found in the promoters of ~50 different genes, including immediate-early genes such as c-fos and Egr-1 (3-5). Studies have also shown that SRF is involved in various cellular processes such as expression of immediate-early and tissue-specific genes, cell proliferation, differentiation and apoptosis (6-10). A previous study has demonstrated that SRF plays a role in tumor progression, specifically in the mesenchymal transition of epithelial tumor cells (11). We have recently reported that expression of SRF correlates with tumor cell dedifferentiation and enhances cell motility and invasiveness in hepatocellular carcinoma (HCC) cells (12).

Papillary thyroid carcinoma (PTC) is the most common thyroid cancer and the incidence of this disease has markedly increased in recent years. However, the expression of SRF in thyroid papillary carcinoma as well as its role has not been investigated. In the present study, we have investigated the expression and localization of SRF in papillary carcinoma, anaplastic carcinoma, adenomatous goiter and follicular adenoma specimens. We also examined the role of SRF in papillary carcinoma cells by overexpression of SRF.

Materials and methods

Patients and specimens. The Human Ethics Committee of Chonbuk National University Medical School approved this study. Paraffin-embedded thyroid specimens were obtained from the archival pathology data of the Department of Pathology at Chonbuk National University Hospital. A total of 132 selected specimens consisted of 63 conventional papillary carcinomas (PTCs), 30 follicular adenomas, 30 adenomatous goiters and 9 anaplastic carcinomas. All of the patients had undergone surgery and did not receive either chemotherapy or radiotherapy before surgical resection. Among the 63 PTCs studied, 41 were >1 cm in diameter (mean size, 1.56 cm) and 22 tumors were <1 cm (mean size, 0.63 cm). Eleven of...
63 patients were diagnosed with a lymph node metastasis. Ten pairs of fresh PTC specimens and adjacent non-tumor thyroid tissues were obtained and were preserved in liquid nitrogen until use.

**Thyroid cancer cell lines.** The human thyroid cancer cell lines NPA (papillary carcinoma), FRO (follicular carcinoma) and ARO (anaplastic carcinoma) were purchased from the Korean Cell Line Bank (Seoul, Korea). These cell lines were cultured in a 37˚C incubator with an atmosphere of 5% CO2. Ten pairs of fresh PTC specimens and adjacent non-tumor thyroid tissues were obtained and were preserved in liquid nitrogen until use.

**Immunohistochemical staining of tissue samples,** the Dako Envision system, that uses dextran polymers conjugated with horseradish peroxidase (Dako, Carpinteria, CA, USA) was performed, as described previously (12). The sections were incubated for 2 h at room temperature with anti-SRF (1:100 dilution; Santa Cruz Biotechnology, Santa Cruz, CA, USA). Peroxidase activity was detected with the enzyme substrate 3-amino-9-ethyl carbazole. For a negative control, the sections were treated in the same manner without the use of a primary antibody.

**Interpretation of SRF immunoreactivity.** Two independent pathologists who had no knowledge of the histopathological data scored the expression of SRF and a high level of concordance (95%) was achieved. The samples that were subjected to immunostaining were rated according to a score calculated by multiplying the intensity of the stain to the area of the stain. The intensity of cell staining was graded according to the following scale: 0, no staining; 1+, mild staining; 2+, moderate staining; 3+ strong staining. The area of staining was evaluated using the following scale: 0, 0-19% of the cells stained positive; 1+, 20-39% of the cells stained positive; 2+, 40-69% of the cells stained positive; 3+, >70% of the cells stained positive. The maximum combined score was 9 and the minimum score was zero.

**Transfection of SRF complementary DNA.** Human SRF complementary DNA (cDNA) (accession number: J03161) was cloned into pcDNA3 (Invitrogen, Carlsbad, CA, USA). The same plasmid without the SRF DNA insert was used as a control vector. All plasmids were amplified in DH5α *Escherichia coli* competent cells (Invitrogen) and were purified using an endo-free plasmid mega-prep kit (Qiagen, Valencia, CA, USA). Transient transfection of NPA, FRO and ARO cells with human SRF or vector cDNA was performed using Lipofectamine (Gibco BRL, Gaithersburg, MD, USA).

**Protein extraction and determination of the SRF and c-Fos protein levels by Western blotting.** Thyroid papillary carcinoma tissues were homogenized using an Ultra-Turrax homogenizer (Ika, Staufen, Germany) in ice-cold lysis buffer (50 mM Tris, pH 7.5, 150 mM NaCl, 0.5% Nonidet P-40) containing 1 mM phenylmethylsulfonyl fluoride, 2 μg/ml leupeptin, 2 μg/ml aprotinin, 5 mM sodium fluoride and 1 mM sodium orthovanadate. The lysates were subjected to Western blotting, as described previously (12). Since SRF is known to regulate expression of genes such as c-Fos, the expression levels of c-Fos and SRF protein were evaluated in an SRF-transfected cell line and thyroid papillary carcinoma tissues. Bound antibody signals were visualized by the use of a chemiluminescence system (Amersham Life Sciences, Arlington Heights, IL, USA). The membranes were stripped and were reprobed with a monoclonal anti-β-actin antibody (Sigma, St. Louis, MO, USA) to normalize protein loading.

**Statistical analysis.** Data are expressed as means ± SE. The differences in the numerical data between groups were evaluated by use of the Mann-Whitney U test. Associations between the expression of SRF and clinicopathological factors were tested by use of Chi-squared test. The following clinicopathological factors were correlated with SRF expression: age and gender, lymph node metastasis and size of tumor (<1 cm vs. ≥1 cm). Comparisons between groups were performed using the Student’s t-test for the migration and invasion assays. A P-value <0.05 was considered as statistically significant.

**Results**

**Overexpression of SRF in thyroid carcinoma specimens.** The results of immunohistochemical analysis are summarized in Table I. When a uniform cut-off of 20% was chosen, SRF was overexpressed in 30 of 63 papillary carcinomas (79%), 6 of 9 anaplastic carcinomas (67%), 18 of 30 follicular adenomas (60%) and 10 of 30 adenomatous hyperplasia (33%), respectively. The mean scores for immunohistochemical staining of SRF from papillary carcinoma or anaplastic carcinoma samples were significantly higher than the mean scores for follicular adenoma or adenomatous hyperplasia samples (Table II). When a uniform cut-off of 10% was chosen, we also obtained a significant difference in the expression of SRF between the malignant and benign lesions (data not shown). Representative immunostaining of tissue samples is shown in Fig. 1. SRF was mainly expressed...
Figure 1. Immunohistochemical expression of SRF. (A and B) Papillary carcinoma cells showed strong positivity for SRF in the nuclei of tumor cells, while non-malignant follicular cells were negative for SRF expression. (C) Follicular adenoma cells showed minimal expression of SRF in the nuclei of tumor cells. Note the strong nuclear expression of SRF in the smooth muscle cells of blood vessel (as internal positive control). (D) Predominant cytoplasmic expression of SRF is seen in papillary carcinoma cells. (E and F) Strong nuclear expression of SRF is seen in anaplastic carcinoma cells.

Table I. Summary of the results of immunohistochemical staining for SRF in various thyroid lesions.

<table>
<thead>
<tr>
<th>Pathology</th>
<th>Positive cases (%)</th>
<th>SRF-positive cells (%)</th>
<th>Intensity</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>&lt;20%</td>
<td>20-39%</td>
</tr>
<tr>
<td>Papillary carcinoma (n=63)</td>
<td>50 (79.3)</td>
<td>13</td>
<td>4</td>
</tr>
<tr>
<td>Anaplastic carcinoma (n=9)</td>
<td>6 (66.6)</td>
<td>3</td>
<td>0</td>
</tr>
<tr>
<td>Follicular adenoma (n=30)</td>
<td>18 (60)</td>
<td>12</td>
<td>7</td>
</tr>
<tr>
<td>Adenomatous hyperplasia (n=30)</td>
<td>10 (33.3)</td>
<td>20</td>
<td>8</td>
</tr>
</tbody>
</table>
in cancer cells with strong nuclear and/or cytoplasmic staining in PTC samples (Fig. 1A). No or minimal staining was observed in normal thyroid follicular cells (Fig. 1B). In addition to the strong staining observed in carcinoma cells, smooth muscle cells of large vessels (as an internal positive control) and occasional stromal cells and endothelial cells showed positive nuclear staining for SRF (Fig. 1C). Among 50 positive cases of PTCs, 22 cases showed nuclear and cytoplasmic staining, 15 showed predominantly nuclear staining and the remaining 13 samples showed cytoplasmic staining only (Fig. 1D). All of the positive cases of the anaplastic carcinomas (91%) specimens with a lymph node metastasis displayed strong SRF expression, indicating an important role of SRF in the formation of lymph node metastases.

Expression of SRF in follicular adenoma or adenomatous hyperplasia was usually <40% of total tumor cells and showed a low expression level. Large papillary carcinomas (≥1 cm) had significantly higher SRF expression than small-sized (<1 cm) tumors (Table III). There was no close correlation between the level of SRF expression and gender or age. Although there was no statistically significance between SRF expression in papillary carcinomas and the presence of a lymph node metastasis, 10 of 11 papillary carcinoma specimens with a lymph node metastasis displayed strong SRF expression, indicating an important role of SRF in the formation of lymph node metastases.

Expression of SRF and c-Fos in thyroid papillary carcinoma tissues. We evaluated the expression of SRF and c-Fos in 10 pairs of PTC tissues and corresponding non-tumor thyroid tissue. Representative SRF and c-Fos expression is shown in Fig. 2. Western blot analyses showed increased expression of spliced variants of SRF in PTC tissues or a different ratio of full-length SRF protein to spliced variants of SRF as compared to the corresponding non-tumor thyroid tissues.

Figure 2. Western blot analysis of SRF and c-Fos in papillary thyroid carcinoma (PTC) tissues. The use of Western blotting demonstrated increased expression of spliced variants of SRF in PTC tissues or a different ratio of full-length SRF protein to spliced variants of SRF as compared to the corresponding non-tumor thyroid tissues.

Expression of SRF in follicular adenoma or adenomatous hyperplasia was usually <40% of total tumor cells and showed a low expression level. In the 50 positive cases of PTCs, 22 cases showed nuclear and cytoplasmic staining, 15 showed predominantly nuclear staining and the remaining 13 samples showed cytoplasmic staining only. All of the positive cases of the anaplastic carcinomas demonstrated nuclear staining only. None of the non-cancerous thyroid tissue samples showed cytoplasmic staining. The SRF expressing cells in papillary carcinoma and anaplastic carcinoma were usually >70% of the total tumor cells and showed strong intensity.

Overexpression of SRF increases expression of c-Fos. To verify the above observations that SRF is overexpressed in thyroid cancer tissues, we examined SRF expression levels in the NPA (papillary carcinoma), FRO (follicular carcinoma) and ARO (anaplastic carcinoma) cell lines. Western blot analyses revealed a different level of SRF expression in each cell line (Fig. 3). As compared to the SRF expression level of

Table II. Comparison of the expression level of SRF in various thyroid lesions.

<table>
<thead>
<tr>
<th>Immunohistochemical SRF scoring (mean ± SE)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Papillary carcinoma (n=63) 5.21±0.43</td>
</tr>
<tr>
<td>Anaplastic carcinoma (n=9) 5.67±1.45</td>
</tr>
<tr>
<td>Follicular adenoma (n=30) 2.30±0.44</td>
</tr>
<tr>
<td>Adenomatous goiter (n=30) 1.13±0.28*</td>
</tr>
</tbody>
</table>

Statistical analysis performed by use of the Mann-Whitney U test. *P>0.001 compared to score of papillary carcinoma.

Table III. Relationship between SRF expression in PTC and tumor size or the presence of a lymph node metastasis.

A. SRF expression

<table>
<thead>
<tr>
<th>Tumor size</th>
<th>&gt;1 cm</th>
<th>&lt;1 cm</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>SRF-positive</td>
<td>38 (60%)</td>
<td>16 (25%)</td>
<td>54 (86%)</td>
</tr>
<tr>
<td>SRF-negative</td>
<td>3 (5%)</td>
<td>6 (10%)</td>
<td>9 (14%)</td>
</tr>
<tr>
<td>Total</td>
<td>41 (65%)</td>
<td>22 (35%)</td>
<td>63 (100%)</td>
</tr>
</tbody>
</table>

Statistical analysis performed by use of the Chi-squared test. P=0.031.

B. Lymph node metastasis

<table>
<thead>
<tr>
<th>Positive lymph node</th>
<th>Negative lymph node</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>SRF-positive</td>
<td>10 (16%)</td>
<td>44 (70%)</td>
</tr>
<tr>
<td>SRF-negative</td>
<td>1 (2%)</td>
<td>8 (12%)</td>
</tr>
<tr>
<td>Total</td>
<td>11 (17%)</td>
<td>52 (83%)</td>
</tr>
</tbody>
</table>

Statistical analysis performed by use of the Chi-squared test. P=0.587.
NPA and FRO cells, the SRF expression level was higher in ARO cells. We also analyzed the expression levels of SRF and an SRF target gene, c-fos, in SRF-transfected NPA, FRO and ARO cells. The use of Western blotting confirmed up-regulation of SRF production in cells transiently transfected with SRF cDNA. In SRF-transfected NPA, FRO and ARO cells, expression levels of SRF were increased by 2.7-, 7.3- and 2.1-fold, respectively. Expression levels of c-Fos were also increased by 1.5-, 3.3- and 3.8-fold, respectively (Fig. 3).

Figure 4. In vitro cell migration and invasion assay. (A) SRF-transfected NPA (papillary carcinoma) cells showed 3.3-fold increased migration with the use of the Boyden chamber assay. (B) In SRF-transfected NPA cells, cell invasion was increased by 2.1-fold when compared with the use of non-transfected control cells.

NPA and FRO cells, the SRF expression level was higher in ARO cells. We also analyzed the expression levels of SRF and an SRF target gene, c-fos, in SRF-transfected NPA, FRO and ARO cells. The use of Western blotting confirmed up-regulation of SRF production in cells transiently transfected with SRF cDNA. In SRF-transfected NPA, FRO and ARO cells, expression levels of SRF were increased by 2.7-, 7.3- and 2.1-fold, respectively. Expression levels of c-Fos were also increased by 1.5-, 3.3- and 3.8-fold, respectively (Fig. 3).

**SRF increases thyroid cancer cell migration and invasion.**

To determine the role of SRF in thyroid cancer cell migration and invasion, we performed a cell migration and invasion assay. Overexpression of SRF in NPA cells increased cell migration by 3.3-fold as compared to cell migration of control cells (Fig. 4A). Overexpression of SRF also increased cell invasion by 2.1-fold as compared to cell invasion of control cells (Fig. 4B) (P<0.05).

**Discussion**

This study demonstrated for the first time the following. a) SRF is significantly up-regulated in PTC and anaplastic carcinoma as compared to SRF expression in follicular
adenoma or adenomatous goiter; b) Western blot analyses show a different expression level of the spliced form of SRF protein and increased expression of c-Fos protein in PTC as compared to expression in non-tumor thyroid tissues; c) SRF expression correlates with tumor size of PTC; d) overexpression of SRF in the thyroid cancer cells enhances the expression of c-Fos; e) 10 of 11 papillary carcinoma (91%) specimens with a lymph node metastasis display strong SRF expression. Furthermore, overexpression of SRF in papillary carcinoma cells enhanced cell motility and invasiveness. These findings clearly indicate the important role of SRF in PTC development and progression.

SRF plays a key role in many cellular processes, including cell cycle regulation, apoptosis, cell growth and differentiation and cell-specific gene regulation (3-10). Accumulating evidence has suggested that SRF plays multiple roles in carcinogenesis and cancer metastasis. The SRF DNA binding activity correlates with increased expression of SRF and squamous epithelial tumor progression, specifically at the transition to an invasive metastatic stage of carcinogenesis (11). We have also shown that expression of SRF correlates with tumor cell dedifferentiation and that overexpression of SRF enhances cell motility and invasiveness of HCC cells (12). In the present study, we found that expression of SRF as well as c-Fos protein is increased in PTC as compared to non-tumor thyroid tissues. Moreover, overexpression of SRF in thyroid cancer cells enhanced the expression level of c-Fos protein, cell migration and invasiveness. In accord with our findings, a previous study has demonstrated that c-Fos expression is significantly up-regulated in thyroid cancer patients (13). c-Fos, an immediate early gene, is one of the SRF targets and is activated by a variety of growth factors and mitogens through several different signaling pathways (14). Indeed, c-Fos has been implicated in the most fundamental processes occurring in mammalian cells such as cell cycle control, (15) cell differentiation, (16) oncogenic transformation and tumor progression (17,18). Together, these findings indicate that up-regulation of SRF and c-Fos expression promotes tumor progression and metastasis of PTC.

Little is known about the expression or role of alternatively spliced isoforms of SRF during cancer development and progression. Previously, Patten et al have demonstrated that the SRFΔ isoform is overexpressed in a human colon cancer cell line derived from a poorly differentiated tumor (19). These investigators have also suggested that SRFΔ isoform is overexpressed in a human colon cancer cell line derived from a poorly differentiated tumor (19). These investigators have also suggested that SRFΔ isoform contributes to epithelial tumorigenesis through the inhibition of apoptosis. Expression of SRFΔ is enhanced in human hypoplastic lungs whereas the spliced form is suppressed during normal bronchial myogenesis (20). In addition, Yang et al have shown that in bleomycin-exposed mouse lungs, the level of SRFΔ is increased mainly due to de novo synthesis (21). They have also observed translocation of SRF/RFΔ into the nuclei from the cytoplasm during the development of myofibroblasts in bleomycin-induced lung injury. Although the antibody used in this study does not distinguish between SRF and its isoforms, our results have demonstrated the presence of nuclear and/or cytoplasmic localization of SRF in PTC cells. We also found increased expression of spliced variants of SRF, predominantly the SRFΔ form, in PTC tissue as compared to the corresponding non-tumor thyroid tissue. These findings suggest that a change in expression of the alternatively spliced isoforms of SRF is closely related to tumorigenesis of PTC. Elucidation of how the alternatively spliced isoforms of SRF regulates cellular function will be valuable in the understanding of how SRF contributes to the tumorigenesis of PTC.

A number of different substances have been evaluated as potential markers in the differential diagnosis of thyroid neoplastic lesions. In this study, we showed significant differences in the expression of SRF among normal thyroid tissue, adenomatous goiter, follicular adenoma and papillary carcinoma and up-regulation for the lymph node metastases of papillary carcinoma. However, there is considerable overlap in SRF immunoreactivity between those with benign lesions and PTC. Although SRF is of potential use in the differential diagnosis of PT and benign nodular lesions, a combination of other immunohistochemical markers with a careful morphological assessment is recommended.

In conclusion, our results indicate that SRF is significantly up-regulated in PTC and anaplastic carcinoma. Moreover, overexpression of SRF in thyroid cancer cells enhances the expression level of the SRF target protein, c-Fos and is associated with tumor progression and metastasis. In addition, we have found a different expression level of the spliced form of SRF in PTC tissues. These findings indicate that altered expression of SRF may have an important role in tumorigenesis and progression of PTC.

Acknowledgements

We thank Professor Mie-Jae Im for her discussion and editorial suggestions. This study was supported by a grant of the Korean Ministry of Education, Science and Technology (The Regional Core Research Program/The Center for Healthcare Technology Development) and by the Ministry of Science and Technology (MoST)/Korea Science and Engineering Foundation (KOSEF) through the Diabetes Research Center at Chonbuk National University (R13-2008-005-0000-0).

References


